Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Summary
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, sunitinib malate, sorafenib tosylate, ponatinib hydrochloride, pacritinib, ruxolitinib, and idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
Timeline
- Start
- 2012-05-11
- Primary completion
- 2017-04-25
- Completion
- 2017-04-30
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to recruit enough eligible subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | — | Oral |
| Subject | Pacritinib | Small molecule | — | Oral |
| Subject | Ponatinib | Small molecule | — | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |
| Subject | Sorafenib | Small molecule | — | Oral |
| Subject | Sunitinib | Small molecule | — | Oral |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |